Skip to main content

Terazosin Pregnancy and Breastfeeding Warnings

Brand names: Hytrin, Tezruly

Terazosin Pregnancy Warnings

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Animal studies have revealed increased fetal resorptions, decreased fetal weight, and an increased number of supernumerary ribs at a dose 60 times the maximum recommended human dose (MRHD). However, these findings were likely secondary to maternal toxicity. Animal studies have also revealed a significant increase in the number of pup deaths at a dose greater than 75 times the MRHD. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Terazosin Breastfeeding Warnings

Caution is recommended. According to some authorities, breastfeeding should be avoided during use of this drug.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

See also

References for pregnancy information

  1. (2001) "Product Information. Hytrin (terazosin)." Abbott Pharmaceutical
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

References for breastfeeding information

  1. (2001) "Product Information. Hytrin (terazosin)." Abbott Pharmaceutical
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer